查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1809919

射频治疗市场按成分、治疗类别、肿瘤类型、适应症和最终用户划分－全球预测，2025-2030

Radioembolization Therapy Market by Component, Treatment Category, Tumor Type, Application Procedure, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计射频增强市场在 2024 年的价值将达到 10.9 亿美元，在 2025 年增长至 11.5 亿美元，到 2030 年将达到 15.4 亿美元，复合年增长率为 5.90%。

主要市场统计数据
基准年2024年 10.9亿美元
预计2025年 11.5亿美元
预测年份 2030 15.4亿美元
复合年增长率（%） 5.90%

射频治疗标誌着复杂肝癌病例先进管理的基石治疗的出现

射频消融术已成为复杂肝肿瘤患者的重要治疗选择。该治疗方法基于数十年的放射学和介入创新，将放射性微球靶向输送至肝血管系统，从而实现肿瘤局部照射，同时保护周围健康组织。随着其有效性和安全性不断得到临床证据的检验，射频消融正从一种实验性方法转变为多模式肿瘤治疗的基石。

面对技术创新和临床突破，我们发现了影响射频治疗格局的关键转折点

随着介入放射学和核子医学的融合，射频治疗的格局正在发生重大变化。显像模式的进步，尤其是锥状射束CT和SPECT-CT融合技术的集成，改善了即时视觉化和治疗后剂量测定，使临床医生能够以前所未有的精度客製化放射剂量。同时，基于玻璃、树脂和聚合物的载体微球设计的改进提高了生物相容性和剂量输送效率，标誌着向以患者为中心的个人化治疗迈出了突破性的一步。

评估 2025 年美国关税对射频消融市场和供应链恢復策略的综合影响

美国将于2025年对进口零件和同位素征收关税，这将为射频治疗市场带来复杂的挑战。专用导管、先进影像处理设备和专有微球技术等零件可能面临关税上调，从而增加医疗机构和设备製造商的采购成本。因此，供应链相关人员必须评估短期财务影响，同时制定策略，确保患者能够负担得起且获得治疗。

按成分、治疗类别、肿瘤类型、适应症和最终用户分類的关键细分洞察

深入探究市场区隔的细微差别，可以发现影响射频疗法应用的关键领域。从组件类别来看，介入耗材领域包括精密的导管输送系统、高精度核子医学相机、先进的放射性微球以及辅助X射线成像平台，这些都对手术的成功至关重要。从治疗方法类别来看，介入性耗材领域分为治癒性治疗和安宁疗护，治癒性治疗方案针对早期恶性肿瘤，而安宁疗护方案则着重于缓解症状并改善晚期患者的生活品质。

了解美洲、欧洲、中东和非洲以及亚太地区射频消融的区域动态

射频治疗的区域动态揭示了全球市场不同的应用和创新模式。在美洲，完善的报销框架和广泛的介入放射中心网络推动了稳定的手术量。北美医疗保健提供者通常是新型微球技术和影像整合的早期采用者，这反映出其在先进肿瘤干预措施方面创新投资的文化。同时，随着区域医疗保健系统扩大复杂手术的诊疗能力，并在多中心临床註册方面开展合作以检验长期疗效，拉丁美洲市场正呈现渐进式增长。

重点介绍产业领导者透过策略联盟和技术投资推动射频治疗领域的创新、协作和竞争成长

射频治疗产业的进步正由一批涉足设备製造、同位素生产和临床服务交付领域的先驱企业推动。一些成熟的介入治疗公司正引领产业发展，建立策略联盟，共同开发下一代微球平台，专注于增强放射性有效载荷并优化动态特性。同时，核子医学专家正在与学术研究机构合作，改进剂量测定模型，并简化新型示踪同位素的核准。

制定可行的策略建议，以增强射频治疗的市场定位、营运效率和合作研究进展

为了充分利用射频消融领域不断发展的机会，产业领导者应采取多方面的策略性倡议。首先，透过多元化的製造地和策略采购协议来优化供应链的弹性，可以缓解关税相关的中断，并保障关键零件的连续性。同时投资数位库存管理和预测性采购分析，可以进一步提升营运敏捷性。

发现支持资料收集、检验流程和分析框架的综合调查方法，以获得深入的市场洞察

我们的调查方法将严谨的第一级和第二级研究与强大的分析框架相结合，以提供全面的市场覆盖和可靠的洞察。首先，我们进行了广泛的文献综述，涵盖同行评审期刊、监管备案文件、临床试验资料库和专有产业报告，以建立基础知识库。此外，我们还对已发表的专利文献和设备註册记录进行了深入分析，以追踪技术趋势和竞争动态。

关于射频消融市场格局的演变轨迹、临床影响和策略要务的总结性评论

我们对射频消融市场的研究揭示了快速的技术发展、不断变化的政策环境和动态的临床通讯协定之间的交汇。导管系统的成熟、新型微球製剂的出现以及数位化规划工具的集成，共同表明该领域将持续创新。同时，关税压力和监管复杂性要求我们采取适应性策略，以维持供应链的完整性和成本效益。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 射频消融术合併查核点抑制剂在肝癌治疗的应用日益增多
  • 扩大转移性大肠直肠肿瘤和神经内分泌肿瘤射频消融的适应症
  • 先进的成像和剂量测定软体的整合增强了个人化治疗计划
  • 钬-166微球扩大了肿瘤标靶射频治疗的选择
  • 亚太地区放射栓塞设备监管核准其渗透至新兴市场
  • 介入放射学与肿瘤学公司之间的策略联盟加速微球创新
  • 门诊放射栓塞通讯协定可减少住院时间并使治疗更具成本效益
  • 人工智慧预测模型改善了射频治疗的患者选择和结果预测
  • 玻璃微球製造技术的进步可以提高特定活性和剂量传递的准确性。
  • 专注于产生真实世界证据来证明长期安全性和有效性

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章射频治疗市场（按组件）

  • 导管
  • 核子医学设备
  • 放射性微球
  • X光设备

第九章射频治疗市场（依治疗类别）

  • 復原
  • 宽慰

第 10 章射频治疗市场（依肿瘤类型）

  • 转移性肝癌
  • 原发性肝癌

第 11 章射频治疗市场（按适应症）

  • 肝臟肿瘤
  • 小叶治疗
  • 部分治疗

第 12 章射频治疗市场（按最终用户）

  • 门诊手术中心
  • 癌症研究所
  • 医院

13.美洲射频治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 14 章欧洲、中东和非洲射频治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太地区射频治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Cook Medical Inc.
    • Boston Scientific Corporation
    • Bayer AG
    • Becton Dickinson & Company
    • Elekta AB
    • Fortis Healthcare Limited
    • Hamilton Health Sciences
    • Mayo Clinic Health System
    • Merit Medical Systems, Inc.
    • Nordion Inc.
    • Northwestern Memorial HealthCare.
    • Radiological Society of North America, Inc.
    • Siemens AG
    • Sirtex Medical Pty Ltd
    • Stryker Corporation
    • Terumo Corporation
    • United HealthCare Services, Inc
    • Medtronic plc

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-562E923A9568

The Radioembolization Therapy Market was valued at USD 1.09 billion in 2024 and is projected to grow to USD 1.15 billion in 2025, with a CAGR of 5.90%, reaching USD 1.54 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.09 billion
Estimated Year [2025] USD 1.15 billion
Forecast Year [2030] USD 1.54 billion
CAGR (%) 5.90%

Charting the Emergence of Radioembolization Therapy as a Cornerstone Treatment Advancing Precision Management of Complex Liver Cancer Cases

Radioembolization therapy has emerged as a vital treatment option for patients confronting complex liver malignancies. Building on decades of radiologic and interventional innovations, this modality integrates targeted delivery of radioactive microspheres into the hepatic vasculature, allowing for localized irradiation of tumors while preserving surrounding healthy tissue. As clinical evidence continues to validate its efficacy and safety profile, radioembolization has transitioned from an experimental approach to a foundational component of multidisciplinary oncology care.

Against this backdrop of evolving clinical practice, understanding the market dynamics that govern the adoption and diffusion of radioembolization therapy is essential. Technological refinements in catheter systems, the development of next-generation radioisotopes, and enhanced imaging guidance tools have collectively elevated procedural precision and patient outcomes. Yet, these advancements also introduce complexities in supply chain management, regulatory compliance, and stakeholder alignment. Therefore, a rigorous exploration of industry forces, regulatory landscapes, and innovation pipelines is necessary to navigate the competitive and clinical terrain effectively.

This executive summary distills the most salient developments shaping the radioembolization ecosystem, offering decision-makers a clear perspective on transformative trends, segmentation insights, regional variances, and actionable recommendations. By contextualizing the therapy's maturation within broader shifts in healthcare delivery and reimbursement, we aim to equip industry leaders, clinical practitioners, and strategic investors with the knowledge needed to capitalize on emerging opportunities and address pivotal challenges.

Unveiling Pivotal Transformative Shifts Reshaping the Radioembolization Therapy Landscape in the Face of Technological Innovation and Clinical Breakthroughs

The radioembolization landscape is undergoing profound transformation as convergence between interventional radiology and nuclear medicine intensifies. Advancements in imaging modalities, particularly the integration of cone-beam CT and SPECT-CT fusion, have elevated real-time visualization and post-treatment dosimetry, enabling clinicians to tailor radiation doses with unprecedented accuracy. Concurrently, the refinement of microsphere design-spanning glass, resin, and emerging polymer-based carriers-has enhanced biocompatibility and dose delivery efficiency, marking a pivotal shift from one-size-fits-all approaches toward patient-centric therapy customization.

Transitional breakthroughs in catheter engineering have also streamlined vascular access and prevented non-target embolization, reducing procedure times and minimizing adverse events. In parallel, the introduction of combined modality protocols, which integrate radioembolization with systemic immunotherapies or intra-arterial chemotherapy, has demonstrated synergistic antitumor effects, broadening the technique's therapeutic scope. These multidisciplinary regimens underscore a move toward precision oncology strategies that leverage locoregional interventions to complement systemic treatments.

Moreover, digital health solutions are reshaping peri-procedural planning and outcome monitoring. Cloud-based analytics and artificial intelligence-driven algorithms are now used to predict vascular anatomy and optimize particle distribution. Consequently, stakeholders from device manufacturers to clinical centers are investing in end-to-end digital workflows, reflecting a transformative trend in how radioembolization services are conceived, delivered, and evaluated.

Assessing the Compounded Consequences of 2025 United States Tariffs on the Radioembolization Therapy Market and Supply Chain Resilience Strategies

The imposition of tariffs by the United States on imported components and isotopes in 2025 presents a complex challenge for the radioembolization market. Components such as specialized catheters, advanced imaging devices, and proprietary microsphere technologies now face increased duties, which can elevate procurement costs for healthcare providers and device manufacturers. As a result, supply chain stakeholders must assess the short-term fiscal impacts while devising strategies that preserve therapy affordability and accessibility for patients.

In response, several manufacturers have explored near-shoring production or establishing additional domestic manufacturing lines to mitigate cost pressures. These ventures require substantial capital investments and regulatory approvals, yet they present an opportunity to fortify supply chain resilience. At the same time, clinical centers are negotiating long-term purchasing agreements and exploring collaborative procurement frameworks to stabilize pricing.

Meanwhile, emerging local isotope production initiatives are gaining traction as a buffer against international tariff volatility. Although these domestic projects may not yet achieve full-scale output parity with established global suppliers, they underscore a strategic pivot toward self-sufficiency. Ultimately, navigating the tariff landscape demands a balanced approach that harmonizes cost containment, regulatory compliance, and uninterrupted access to critical radioembolization technologies.

Extracting Key Segmentation Insights to Illuminate Component, Treatment Category, Tumor Type, Application Procedure, and End-User Dynamics

Delving into the nuances of market segmentation reveals pivotal areas shaping radioembolization therapy adoption. Examining component categories, the sphere of interventional consumables spans sophisticated catheter delivery systems, high-precision nuclear medicine cameras, advanced radioactive microspheres, and supplementary X-ray imaging platforms, each integral to procedural success. Transitioning to treatment categorizations, the divide between curative and palliative intent underscores divergent clinical pathways, with curative protocols targeting early-stage malignancies and palliative regimens focusing on symptom relief and quality of life enhancement for advanced disease stages.

The segmentation by tumor type further refines market understanding, as practices for addressing metastatic liver cancer diverge significantly from those treating primary hepatocellular carcinoma. Distinct tumor biology, patient comorbidities, and response profiles guide clinical decision-making and device selection criteria. In the context of application procedures, practitioners differentiate between whole liver interventions, lobar therapy focused on a specific hepatic lobe, and highly targeted segmental therapy aiming at localized tumor nodules. This granularity enables personalized treatment planning and optimizes risk-benefit assessments.

Equally important is the end-user segmentation, where ambulatory surgical centers emphasize cost-efficient procedural throughput, cancer research institutes prioritize integration with clinical trials and experimental protocols, and hospitals leverage comprehensive multidisciplinary teams to deliver complex interdepartmental care. By synthesizing insights across component, treatment category, tumor type, application procedure, and end-user dimensions, stakeholders can pinpoint strategic priorities for innovation, market expansion, and targeted commercialization efforts.

Decoding Regional Dynamics in the Radioembolization Therapy Domain Across Americas, Europe Middle East & Africa, and Asia-Pacific Specificities

Regional dynamics in radioembolization therapy reveal differentiated patterns of adoption and innovation across global markets. In the Americas, established reimbursement frameworks and an extensive network of interventional radiology centers drive consistent procedural volumes. North American providers are often early adopters of novel microsphere technologies and imaging integrations, reflecting a culture of innovation and investment in advanced oncologic interventions. Meanwhile, Latin American markets exhibit incremental growth as regional healthcare systems expand capacity for complex procedures and collaborate on multicenter clinical registries to validate long-term outcomes.

Transitioning to Europe, Middle East & Africa, diverse regulatory environments and heterogeneous healthcare infrastructures present both challenges and opportunities. In Western Europe, centralized health technology assessments guide procurement strategies, often prioritizing cost-effectiveness data and real-world evidence to support therapy adoption. In contrast, emerging markets across the Middle East and Africa are gradually enhancing specialized treatment centers, fostering partnerships with global manufacturers to establish training programs and supply networks.

The Asia-Pacific region manifests robust growth trajectories, driven by aging populations and rising cancer incidence rates. Countries such as Japan and South Korea lead in clinical research, exploring advanced dosimetry protocols and combination therapy trials. Meanwhile, rapidly developing markets in Southeast Asia and Australia are scaling up institutional capabilities, investing in workforce training and forging public-private alliances to broaden patient access to radioembolization therapy across urban and regional centers.

Highlighting Leading Industry Players Driving Innovation, Collaboration, and Competitive Growth in Radioembolization Therapy Through Strategic Alliances and Technology Investments

Industry progress in radioembolization therapy is propelled by a select cohort of pioneering companies that span device manufacturing, isotope production, and clinical service delivery. Leading the pack, established interventional entities have secured strategic collaborations to co-develop next-generation microsphere platforms, focusing on enhanced radioactive payloads and optimized hydrodynamic properties. At the same time, nuclear medicine specialists collaborate with academic research institutions to refine dosimetric models and streamline approvals for novel tracer isotopes.

Concurrently, a wave of emerging players has introduced complementary products that address procedural bottlenecks. Some firms specialize in advanced catheter tip designs that minimize vascular trauma, while others deliver integrated imaging solutions that merge multiple modalities within a unified operating suite. These advancements are frequently supported by joint ventures, distribution agreements, and technology transfer partnerships designed to accelerate global market penetration.

Moreover, several companies have adopted a holistic approach to customer engagement, offering comprehensive training programs, digital planning tools, and post-procedure support services. By cultivating these ecosystem partnerships, market leaders reinforce their competitive positioning and pave the way for iterative improvements that benefit clinicians and patients alike.

Formulating Actionable Strategic Recommendations to Enhance Market Positioning, Operational Efficiency, and Collaborative Advancement in Radioembolization Therapy

To capitalize on the evolving landscape of radioembolization therapy, industry leaders should pursue a multifaceted strategic agenda. First, optimizing supply chain resilience through diversified manufacturing footprints and strategic sourcing agreements will mitigate tariff-related disruptions and safeguard continuity of critical components. Parallel investments in digital inventory management and predictive procurement analytics can further enhance operational agility.

Second, fostering cross-disciplinary collaboration between interventional radiologists, nuclear medicine specialists, and oncologists is crucial. Establishing joint research consortia and multicenter clinical trials will generate robust evidence for combination therapies, thereby strengthening reimbursement cases and accelerating regulatory approvals. In addition, integrating real-world data capture into routine practice will support iterative refinements of procedural protocols and patient selection criteria.

Third, enhancing end-user engagement through tailored educational programs and decision-support tools will drive broader adoption. By developing virtual training simulators and outcome benchmarking dashboards, stakeholders can equip clinical teams with the knowledge and confidence to deliver advanced radioembolization services. Finally, expanding partnerships with payers and health technology assessment bodies to demonstrate long-term value and cost-effectiveness will facilitate more predictable reimbursement pathways and unlock new markets for sustainable growth.

Elucidating the Comprehensive Research Methodology Underpinning Data Collection, Validation Processes, and Analytical Frameworks for In-Depth Market Insights

Our research methodology combines rigorous primary and secondary data collection with robust analytical frameworks to ensure comprehensive market coverage and credible insights. Initially, an extensive literature review encompassed peer-reviewed journals, regulatory filings, clinical trial databases, and proprietary industry reports to establish a foundational knowledge base. This was complemented by an exhaustive analysis of publicly available patent documents and device registry records to track technological trends and competitive developments.

Simultaneously, primary research efforts engaged over two hundred stakeholders across the ecosystem, including interventional radiologists, nuclear medicine experts, procurement specialists, and regulatory authorities. Structured interviews and in-depth surveys captured qualitative perspectives on procedural workflows, adoption barriers, and emerging clinical practices. To validate these insights, data triangulation techniques compared multiple information sources, identifying convergent patterns and resolving discrepancies.

Quantitative modeling techniques were applied to cost structures, pricing trends, and utilization rates, while scenario analyses explored potential impacts of tariff policies, regulatory changes, and technological breakthroughs. Throughout the process, a panel of senior clinicians and industry veterans provided continuous input, ensuring that assumptions reflected real-world practice and that findings were grounded in current clinical and commercial realities. This integrated approach delivers a transparent, replicable framework for understanding the radioembolization therapy market in its full complexity.

Drawing Conclusive Perspectives on the Evolutionary Trajectory, Clinical Impact, and Strategic Imperatives of the Radioembolization Therapy Market Landscape

Our examination of the radioembolization therapy market underscores an intersection of rapid technological evolution, shifting policy environments, and dynamic clinical protocols. The maturation of catheter systems, the advent of novel microsphere formulations, and the integration of digital planning tools collectively signify a sector poised for continued innovation. At the same time, tariff pressures and regulatory intricacies demand adaptive strategies to maintain supply chain integrity and cost efficiencies.

Segmentation analysis reveals that differentiated approaches to component selection, treatment intent, tumor biology, procedural techniques, and care settings will shape competitive landscapes and patient access. Regional variances highlight the necessity of tailored adoption roadmaps, reflecting localized reimbursement frameworks, clinical preferences, and infrastructure capabilities. Furthermore, collaboration among device manufacturers, clinical centers, and research consortia emerges as a critical catalyst for advancing evidence-based practice and accelerating market expansion.

Looking ahead, the capacity to harness real-world data, foster interdisciplinary partnerships, and demonstrate long-term value through rigorous health economics assessments will determine which stakeholders lead the next phase of growth. Ultimately, the strategic imperatives identified in this report provide a clear blueprint for navigating complexity, driving innovation, and delivering enhanced patient outcomes in the radioembolization therapy domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Growing use of radioembolization combined with checkpoint inhibitors in liver cancer management
  • 5.2. Expansion of indications for metastatic colorectal and neuroendocrine tumor radioembolization therapies
  • 5.3. Integration of advanced imaging and dosimetry software enhances personalized treatment planning
  • 5.4. Adoption of holmium-166 microspheres broadens radioembolization options for tumor targeting
  • 5.5. Regulatory approval of radioembolization devices in Asia Pacific drives emerging market penetration
  • 5.6. Strategic alliances between interventional radiology and oncology firms accelerate microsphere innovation
  • 5.7. Outpatient radioembolization protocols reduce hospital stays and drive procedural cost efficiencies
  • 5.8. AI-driven predictive modeling improves patient selection and outcome forecasting in radioembolization therapy
  • 5.9. Advances in glass microsphere manufacturing enhance specific activity and dose delivery precision
  • 5.10. Increasing focus on real-world evidence generation to demonstrate long-term safety and efficacy profiles

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Radioembolization Therapy Market, by Component

  • 8.1. Introduction
  • 8.2. Catheters
  • 8.3. Nuclear Medicine Equipment
  • 8.4. Radioactive Microspheres
  • 8.5. X-Ray Equipment

9. Radioembolization Therapy Market, by Treatment Category

  • 9.1. Introduction
  • 9.2. Curative
  • 9.3. Palliative

10. Radioembolization Therapy Market, by Tumor Type

  • 10.1. Introduction
  • 10.2. Metastatic Liver Cancer
  • 10.3. Primary Liver Cancer

11. Radioembolization Therapy Market, by Application Procedure

  • 11.1. Introduction
  • 11.2. Liver Tumour
  • 11.3. Lobar Therapy
  • 11.4. Segmental Therapy

12. Radioembolization Therapy Market, by End-User

  • 12.1. Introduction
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Cancer Research Institutes
  • 12.4. Hospitals

13. Americas Radioembolization Therapy Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Radioembolization Therapy Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Radioembolization Therapy Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Cook Medical Inc.
    • 16.3.2. Boston Scientific Corporation
    • 16.3.3. Bayer AG
    • 16.3.4. Becton Dickinson & Company
    • 16.3.5. Elekta AB
    • 16.3.6. Fortis Healthcare Limited
    • 16.3.7. Hamilton Health Sciences
    • 16.3.8. Mayo Clinic Health System
    • 16.3.9. Merit Medical Systems, Inc.
    • 16.3.10. Nordion Inc.
    • 16.3.11. Northwestern Memorial HealthCare.
    • 16.3.12. Radiological Society of North America, Inc.
    • 16.3.13. Siemens AG
    • 16.3.14. Sirtex Medical Pty Ltd
    • 16.3.15. Stryker Corporation
    • 16.3.16. Terumo Corporation
    • 16.3.17. United HealthCare Services, Inc
    • 16.3.18. Medtronic plc

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. RADIOEMBOLIZATION THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. RADIOEMBOLIZATION THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. RADIOEMBOLIZATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. RADIOEMBOLIZATION THERAPY MARKET: RESEARCHAI
  • FIGURE 26. RADIOEMBOLIZATION THERAPY MARKET: RESEARCHSTATISTICS
  • FIGURE 27. RADIOEMBOLIZATION THERAPY MARKET: RESEARCHCONTACTS
  • FIGURE 28. RADIOEMBOLIZATION THERAPY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. RADIOEMBOLIZATION THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CATHETERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY NUCLEAR MEDICINE EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY NUCLEAR MEDICINE EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY RADIOACTIVE MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY RADIOACTIVE MICROSPHERES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY X-RAY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY X-RAY EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CURATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CURATIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PALLIATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PALLIATIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY METASTATIC LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY METASTATIC LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PRIMARY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PRIMARY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LIVER TUMOUR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LIVER TUMOUR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LOBAR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LOBAR THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY SEGMENTAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY SEGMENTAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 48. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 49. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 50. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 51. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 54. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 55. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 56. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 57. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 59. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 60. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 62. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 63. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 65. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 66. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 67. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 68. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 69. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 70. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 71. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 72. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 73. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 74. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 75. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 78. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 79. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 80. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 81. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 82. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 83. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 84. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 85. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 88. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 89. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 90. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 91. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 92. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 93. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 94. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 95. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 98. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 99. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 100. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 101. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 102. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 103. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 104. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 105. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 108. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 109. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 110. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 133. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 134. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 135. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 136. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 137. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 140. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 141. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 143. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 144. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 145. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 146. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 147. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 150. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 151. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 152. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 153. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 154. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 155. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 156. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 157. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 160. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 161. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 162. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 163. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 164. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 165. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 166. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 167. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 170. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 171. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 172. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 173. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 174. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 175. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 176. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 177. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 180. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 181. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 194. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 196. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 200. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 204. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 206. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 210. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 212. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 213. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 214. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 215. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 216. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 217. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 220. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 221. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 222. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 223. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 224. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 225. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 226. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 230. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 232. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 233. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 234. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 235. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 236. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 237. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 240. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 241. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 242. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 243. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 244. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 245. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 246. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 247. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 250. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 251. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 253. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 254. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 255. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 256. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 257. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 259. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 260. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 261. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 263. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 264. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 265. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 266. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 267. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 270. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 271. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 272. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 273. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 274. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 275. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 276. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 277. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 280. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 281. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 282. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 283. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 284. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 285. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 286. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 287. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 290. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 291. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 293. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 294. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 295. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 296. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 297. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 300. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 301. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 302. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 303. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 304. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 305. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 306. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 307. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 310. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 311. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 312. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 313. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 314. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 315. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 316. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 317. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 320. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 321. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MIL